Loading... Please wait...
Sort by:

 

FirstView NPS+

An expanded view of brand loyalty among doctors

Actionable metrics to help you make better brand decisions

 

Net Promoter Score (NPS) is an easy way to measure brand health, but it doesn’t tell you how to improve it. NPS+ turns your Net Promoter Score into actionable information by answering key questions about brand loyalty

 

Each NPS+ report examines doctors’ relationships with the brands used to treat a major disease area—measuring brand loyalty and showing you how it affects your market share. NPS+ also examines “brand DNA”, revealing in doctors’ own words what brands mean to them.

 

Instead of one simple metric, NPS+ gives you a detailed picture of brand health that highlights areas for improvement, and helps you see exactly what steps you need to take next.

  • Medical Affairs Reputations: HIV (US) 2017
    Learn More Medical Affairs Reputations: HIV (US) 2017
    Survey shows medical affairs teams must be more active and provide better information Doctors say medical affairs teams for 10 major HIV treatments could be doing a better job. In the past 6 months, only one of those...
  • Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2017
    Learn More Medical Affairs Reputations: Renal Cell Carcinoma (EU5) 2017
    Better information provision could give your medical affairs team a boost with doctors Is your medical affairs team giving doctors the information they need? Maybe not, according to our survey of 100 medical oncologists...
  • Medical Affairs Reputations: Renal Cell Carcinoma (US) 2017
    Learn More Medical Affairs Reputations: Renal Cell Carcinoma (US) 2017
    Better information provision could give your medical affairs team a boost with doctors Is your medical affairs team giving doctors the information they need? Maybe not, according to our survey of 100 medical oncologists...
  • NPS+ Psoriasis 2017 (EU)
    Learn More NPS+ Psoriasis 2017 (EU)
    Biosimilars take the biggest hit as doctors voice dissatisfaction with psoriasis treatments Dermatologists say they’re satisfied with available psoriasis treatments. So why did only 3 of the brands we asked them...
  • NPS+ Psoriasis 2017 (US)
    Learn More NPS+ Psoriasis 2017 (US)
    Two psoriasis treatments get a thumbs-down from otherwise satisfied doctors Dermatologists may be happy with psoriasis treatments overall, but they gave dismal satisfaction scores to 2 of the 8 brands we surveyed them...
  • NPS+ HIV (US) 2017
    Learn More NPS+ HIV (US) 2017
    Doctors upbeat about HIV treatments, but satisfaction runs highest for 3 brands Doctors may be satisfied with available HIV treatments overall, but when we surveyed 100 US-based infectious disease specialists and...
  • NPS+ HIV (EU5) 2017
    Learn More NPS+ HIV (EU5) 2017
    Doctors upbeat about HIV treatments, but satisfaction runs highest for 2 brands Doctors may be satisfied with available HIV treatments overall, but when we surveyed 150 EU5-based infectious disease specialists and...
  • NPS+ Renal Cell Carcinoma (EU5) 2017
    Learn More NPS+ Renal Cell Carcinoma (EU5) 2017
    How ‘healthy’ are brand loyalty and satisfaction levels amongst RCC oncologists? According to this latest survey, the top three ‘healthiest’ Renal Cell Carcinoma (RCC) brands in Europe with the...
  • NPS+ Renal Cell Carcinoma (US) 2017
    Learn More NPS+ Renal Cell Carcinoma (US) 2017
    How ‘healthy’ are brand loyalty and satisfaction levels amongst RCC oncologists? With some relatively recent entrants gaining ground amongst a field of established drugs, how is brand loyalty faring across...
  • NPS+ Parkinson’s Disease (EU5) 2017
    Learn More NPS+ Parkinson’s Disease (EU5) 2017
    Low scores for 7 of 8 surveyed brands reflect widespread dissatisfaction among doctors Neurologists in the EU5 countries are not happy with available Parkinson’s disease treatments, and it shows. According to our...
  • NPS+ Parkinson’s Disease (US) 2017
    Learn More NPS+ Parkinson’s Disease (US) 2017
    Only three drugs get positive satisfaction scores from neurologists. Is your brand one of them? US neurologists are satisfied with available Parkinson’s disease treatments, but that doesn’t mean...
  • NPS+ Cancer Pain (EU5) 2017
    Learn More NPS+ Cancer Pain (EU5) 2017
    Only three drugs get positive satisfaction scores from oncologists. Is your brand one of them? In our survey of ten cancer pain drugs, only three brands earned positive satisfaction scores from doctors in the EU5...
  • NPS+ Cancer Pain (US) 2017
    Learn More NPS+ Cancer Pain (US) 2017
    Top brand has an insurmountable lead. Can your brand narrow the gap? In our survey of 11 cancer pain drugs, only one brand earned a positive satisfaction score from US doctors. The runaway favourite, this brand is...
  • NPS+ Multiple Myeloma (EU5) 2016
    Learn More NPS+ Multiple Myeloma (EU5) 2016
    Two brands are way out front in an otherwise unsatisfied market. Where does your brand rank? According to our survey of 150 medical oncologists and haematologists, doctors in the EU5 countries are not happy with...
  • NPS+ Multiple Myeloma (US) 2016
    Learn More NPS+ Multiple Myeloma (US) 2016
    Overall satisfaction is high, but three brands are way ahead. Can your brand catch up? Our survey of 100 medical oncologists and haematologists shows that while US doctors are happy with available myeloma therapies,...
  • NPS+ Multiple Sclerosis (EU5) 2016
    Learn More NPS+ Multiple Sclerosis (EU5) 2016
    One brand comes out ahead as low satisfaction scores plague MS therapies. Is your brand far behind? Multiple Sclerosis (MS) therapies have a big perception problem in the EU5 countries. Nearly half of the doctors we...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved